Substituted fused heterocycles as c-Met tyrosine kinase inhibitors

1. A compound according to Formula I

or a pharmaceutically acceptable salt thereof,

wherein:

is a monocyclic 5-18 membered heterocyclyl, represented by the following formula:

wherein Ring A contains 1-14 additional atoms independently selected from the group consisting of carbon, oxygen and nitrogen;

R 1 is halogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, heteroaryl, heterocyclyl, C 1-8 alkanoyl, C 1-8 alkoxycarbonyl, C 1-8 alkylsulfinyl, C 1-8 alkylsulfonyl, arylsulfonyl, cyano, nitro, hydroxy, amino, carboxy, oxo, carbamoyl, C 1-8 alkoxy, C 2-8 alkenyloxy, C 2-8 alkynyloxy, C 1-8 alkylthio, N—(C 1-8 alkyl)carbamoyl, N,N-di(C 1-8 alkyl)carbamoyl, C 1-8 alkanoyloxy, C 1-8 alkanoylamino, C 3-8 alkynoylamino, N—(C 1-8 alkyl)sulfamoyl, or N,N-di(C 1-8 alkyl) sulfamoyl;

m is 0, 1, 2, or 3;

A 1 and A 2 are each independently ═N— or ═C(R 2 )—;

R 2 is halogen, hydrogen, trihalomethyl, —CN, —NO 2 , OR 5 , —NR 5 R 6 , —S(O) 0-2 R 5 , —SO 2 NR 5 R 6 , —CO 2 R 5 , —C(O)NR 5 R 6 , —N(R 3 )SO 2 R 5 , —N(R 5 )C(O)R 6 , —N(R 5 )CO 2 R 6 , —C(O)R 5 , or lower alkyl; wherein

R 5 and R 6 are each independently hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl, heteroaryl, heterocyclyl, C 1-8 alkanoyl, C 1-8 alkoxycarbonyl, C 1-8 alkylsulfinyl, C 1-8 alkylsulfonyl, arylsulfonyl, cyano, nitro, hydroxy, amino, carboxy, oxo, carbamoyl, C 1-8 alkoxy, C 2-8 alkenyloxy, C 2-8 alkynyloxy, C 1-8 alkylthio, N—(C 1-8 alkyl) carbamoyl, N,N-di(C 1-8 alkyl) carbamoyl, C 1-8 alkanoyloxy, C 1-8 alkanoylamino, C 3-8 alkynoylamino, N—(C 1-8 alkyl) sulfamoyl, N,N-di C 1-8 alkyl)sulfamoyl, C 1-8 alkylaryl, C 1-8 alkylheteroaryl, or C 1-8 alkylheterocyclyl;

n is 0, 1, 2, 3, or 4;

A 3 is ═N—, ═C(H)—, or ═C(CN)—;

X is NR 20 , CHR 21 , O, or S; wherein R 20 and R 21 are each independently H or C 1-8 alkyl;

Z is —NR 3 R 4 or Formula II, wherein

R 9 and R 10 are each independently C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl optionally substituted with halogen, heteroaryl optionally substituted with halogen, heterocyclyl, C 1-8 alkanoyl, C 1-8 alkoxycarbonyl, C 1-8 alkylsulfinyl, C 1-8 alkylsulfonyl, or arylsulfonyl;

R 3 is hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 alkanoyl, C 1-8 alkoxycarbonyl, C 1-8 alkylsulfinyl, C 1-8 alkylsulfonyl, arylsulfonyl, cyano, nitro, hydroxy, amino, carboxy, oxo, carbamoyl, C 1-8 alkoxy, C 2-8 alkenyloxy, C 2-8 alkynyloxy, C 1-8 alkylthio, N—(C 1-8 alkyl)carbamoyl, N,N-di(C 1-8 alkyl)carbamoyl, C 1-8 alkanoyloxy, C 1-8 alkanoylamino, C 3-8 alkynoylamino, N—(C 1-8 alkylsulfamoyl, or N,N-di(C 1-8 alkylsulfamoyl;

R 4 is Formula III, Formula IV, Formula V, Formula VI, or Formula VII:

wherein,

B 1 is

Q 1 is C(R 5 ) 2 ;

B 2 is NHQ 2 ;

Q 2 is aryl optionally substituted with halogen, heteroaryl optionally substituted with halogen, heterocyclyl, C 1-8 alkylaryl, C 1-8 alkylheteroaryl, or C 1-8 alkylheterocyclyl;

or, B 1 and B 2 , together with the —C(O)— group to which they are bonded, form a 5 to 10 member heteroaryl, or heterocyclyl;

Q 3 is hydrogen, aryl optionally substituted with halogen, heteroaryl optionally substituted with halogen, heterocyclyl, C 1-8 alkylaryl, C 1-8 alkylheteroaryl, or C 1-8 alkylheterocyclyl;

X 1 is NR 8 or CR 7 R 8 ;

and R 7 , R 8 and R 11 are each independently hydrogen, halogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, aryl optionally substituted with halogen, heteroaryl optionally substituted with halogen, heterocyclyl, C 1-8 alkanoyl, C 1-8 alkoxycarbonyl, C 1-8 alkylsulfinyl, C 1-8 alkylsulfonyl, N—(C 1-8 alkyl)carbamoyl, N,N-di(C 1-8 alkyl)carbamoyl, C 1-8 alkanoyloxy, arylsulfonyl, cyano, nitro, hydroxy, amino, carboxy, oxo, carbamoyl, C 1-8 alkoxy, C 2-8 alkenyloxy, C 2-8 alkynyloxy, C 1-8 alkylthio, C 1-8 alkanoylamino, C 3-8 alkynoylamino, N—(C 1-8 alkyl)sulfamoyl, N,N-di(C 1-8 alkyl)sulfamoyl, C 1-8 alkylaryl, C 1-8 alkylheteroaryl, or C 1-8 alkylheterocyclyl.

2. The compound according to claim 1 , wherein R 1 is halogen.

3. The compound according to claim 2 , wherein R 1 is fluoro.

4. The compound according to claim 1 , wherein R 2 is halogen or hydrogen.

5. The compound according to claim 4 , wherein R 2 is fluoro.

6. The compound according to claim 1 , wherein Q 2 is phenyl or halo-substituted phenyl.

7. The compound according to claim 6 , wherein Q 2 is 2-fluorophenyl or 4-fluorophenyl.

8. The compound according to claim 1 , wherein Q 3 is phenyl or halo-substituted phenyl.

9. The compound according to claim 8 , wherein Q 3 is halo-substituted phenyl.

10. The compound according to claim 9 , wherein Q 3 is fluoro-substituted phenyl.

11. The compound according to claim 1 , wherein R 7 is C 1-6 alkyl, phenyl, or halo-substituted phenyl.

12. The compound according to claim 11 , wherein R 7 is —CH 3 or fluoro-substituted phenyl.

13. The compound according to claim 1 , wherein R 7 , R 8 and R 11 are each independently hydrogen, halogen, or C 1-8 alkyl.

14. The compound according to claim 13 , wherein R 7 , R 8 and R 11 are each hydrogen.

15. The compound according to claim 1 , wherein

is a monocyclic 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, or 18 membered heterocyclyl.

16. The compound according to claim 1 , wherein

is a monocyclic 5, 7, 9, 11, 12, or 18 membered heterocyclyl.

17. The compound according to claim 1 , wherein

contains 1, 2, 3, 4, 5, or 6 heteroatoms each independently selected from the group consisting of oxygen and nitrogen.

18. The compound according to claim 1 , wherein

is

19. The compound according to claim 18 , wherein

is

20. The compound according to claim 1 , wherein m is 0, 1, or 2.

21. The compound according to claim 1 , wherein R 1 is fluoro and m is 1 or 2.

22. The compound according to claim 1 , wherein A 2 is ═N—.

23. The compound according to claim 1 , wherein A 1 is ═C(R 2 )—, and R 2 is halogen, hydrogen, trihalomethyl, —CN, —NO 2 , or —NH 2 .

24. The compound according to claim 1 , wherein A 1 is ═CH— and A 2 is ═N—.

25. The compound according to claim 1 , wherein A 1 is ═CH— or ═CF—, and A 2 is ═CH—.

26. The compound according to claim 1 , wherein A 3 is ═N— or ═C(H)—.

27. The compound according to claim 1 , wherein X is NR 20 or CHR 21 , and R 20 and R 21 are each independently H or C 1-3 alkyl.

28. The compound according to claim 1 , wherein X is O, S, or NH.

29. The compound according to claim 1 , wherein R 3 is C 1-4 alkyl.

30. The compound according to claim 1 , wherein R 3 is hydrogen.

31. The compound according to claim 1 , wherein each Q 1 is CH 2 .

32. The compound according to claim 1 , wherein R 4 is

33. The compound according to claim 1 , wherein X 1 is NR 8 and R 8 is C 1-6 alkyl.

34. The compound according to claim 1 , wherein X 1 is NCH 3 .

35. The compound according to claim 1 , wherein R 8 is hydrogen.

36. The compound according to claim 1 , wherein R 5 and R 6 are each independently hydrogen.

37. The compound according to claim 1 , wherein Z is

38. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

5-(4-Fluoro-phenyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide;

1-(4-Fluoro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide;

Cyclopropane-1,1-dicarboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide;

3-(4-Fluoro-phenyl)-2-oxo-imidazolidine-1-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide;

2-(4-Fluoro-phenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide;

2-(4-Fluoro-phenylamino)-5-[5-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-yloxy)-pyridin-2-yl]-3-methyl-3H-pyrimidin-4-one;

5-[5-([1,3]Dioxolo[4,5-g]quinazolin-8-yloxy)-pyridin-2-yl]-2-(4-fluoro-phenylamino)-3-methyl-3H-pyrimidin-4-one;

5-[5-(2,2-Difluoro-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy)-pyridin-2-yl]-2-(4-fluoro-phenylamino)-3-methyl-3H-pyrimidin-4-one;

5-(4-Fluoro-phenyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid [4-([1,3]dioxolo[4,5-g]quinazolin-8-yloxy)-3-fluoro-phenyl]-amide;

5-(4-Fluoro-phenyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide;

1-(4-Fluoro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide;

2-(4-Fluoro-phenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide;

Cyclopropane-1,1-dicarboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide;

3-(4-Fluoro-phenyl)-2-oxo-imidazolidine-1-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]amide;

5-[5-(2,2-Difluoro-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy)-pyridin-2-yl]-2-(2-fluoro-phenylamino)-3-methyl-3H-pyrimidin-4-one;

5-[5-(2,2-Difluoro-[1,3]dioxolo[4,5-g]quinazolin-8-yloxy)-pyridin-2-yl]-2-(phenylamino)-3-methyl-3H-pyrimidin-4-one;

5-(4-Fluoro-phenyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-ylamino)-phenyl]-amide;

5-(4-Fluoro-phenyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1-aza-cyclododeca[b]naphthalen-4-ylsulfanyl)-phenyl]-amide;

3-Methyl-2-phenylamino-5-[5-(2,5,7,10-tetraoxa-14,16-diaza-tricyclo[9.8.0.013,18]nonadeca-1(11),12,14,16,18-pentaen-17-yloxy)-pyridin-2-yl]-3H-pyrimidin-4-one;

5-[5-(8,9-Dihydro-7H-6,10-dioxa-1,3-diaza-cyclohepta[b]naphthalen-4-yloxy)-pyridin-2-yl]-2-(4-fluoro-phenylamino)-3-methyl-3H-pyrimidin-4-one;

2-(4-Fluoro-phenylamino)-3-methyl-5-[5-(9-methyl-8,9,10,11-tetrahydro-7H-6,12-dioxa-1,3,9-triaza-cyclonona[b]naphthalen-4-yloxy)-pyridin-2-yl]-3H-pyrimidin-4-one;

2-(4-Fluoro-phenylamino)-3-methyl-5-[5-(7,8,10,11-tetrahydro-6,9,12-trioxa-1,3-diaza-cyclonona[b]naphthalen-4-yloxy)-pyridin-2-yl]-3H-pyrimidin-4-one;

5-[5-(8,9-Dihydro-7H-6,10-dioxa-1-aza-cyclohepta[b]naphthalen-4-yloxy)-pyridin-2-yl]-2-(4-fluoro-phenylamino)-3-methyl-3H-pyrimidin-4-one;

2-(4-Fluoro-phenylamino)-3-methyl-5-[5-(9-methyl-8,9,10,11-tetrahydro-7H-6,12-dioxa-1,9-diaza-cyclonona[b]naphthalen-4-yloxy)-pyridin-2-yl]-3H-pyrimidin-4-one;

2-(4-Fluoro-phenylamino)-3-methyl-5-[5-(7,8,10,11-tetrahydro-6,9,12-trioxa-1-aza-cyclonona[b]naphthalen-4-yloxy)-pyridin-2-yl]-3H-pyrimidin-4-one;

3-Methyl-2-phenylamino-5-[5-(2,5,7,10-tetraoxa-14-aza-tricyclo[9.8.0.013,18]nonadeca-1(11),12,14,16,18-pentaen-17-yloxy)-pyridin-2-yl]-3H-pyrimidin-4-one;

5-[5-(2,2-Difluoro-[1,3]dioxolo[4,5-g]quinolin-8-yloxy)-pyridin-2-yl]-2-(2-fluoro-phenylamino)-3-methyl-3H-pyrimidin-4-one;

5-[5-(2,2-Difluoro-[1,3]dioxolo[4,5-g]quinolin-8-yloxy)-pyridin-2-yl]-2-(phenylamino)-3-methyl-3H-pyrimidin-4-one;

5-(4-Fluoro-phenyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-ylamino)-phenyl]-amide;

5-(4-Fluoro-phenyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-ylsulfanyl)-phenyl]-amide; and

5-[5-(2,5,8,11,14,17-Hexaoxa-21-aza-tricyclo[16.8.0.020,25]hexacosa-1(18),19,21,23,25-pentaen-24-yloxy)-pyridin-2-yl]-3-methyl-2-phenylamino-3H-pyrimidin-4-one.

39. A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable excipient.

40. The pharmaceutical composition according to claim 39 , wherein the weight ratio of the compound to the excipient ranges from 0.0001 to 10.

41. A method for inhibiting c-Met tyrosine kinase activity in a mammal, comprising administering to said mammal a therapeutically effective amount of at least one compound according to claim 1 .

42. The method according to claim 41 , wherein the mammal suffers from a disease or disorder selected from the group consisting of cancer, cancer metastasis, a cardiovascular disease, an immunological disorder, and an ocular disorder.

43. The method according to claim 42 , wherein the cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal cancer, pancreatic cancer, head cancer, neck cancer, gastric cancer, hereditary papillary renal cell carcinoma, and childhood hepatocellular carcinoma.